Agilent Technologies : Q2'25 Results Presentation

Published: 2025-05-28 16:58:06 ET A

Published on 05/28/2025 at 16:58

Q2 FY2025

FINANCIAL RESULTS

OVERVIEW

May 28, 2025

$

Agilent

Q225 Results

Q2 revenue growth exceeded the high end of our

Revenue

Operating Margin

EPS

guidance range in spite of the highly dynamic market environment during the quarter. On the bottom line,

$1.67B

+6.0% reported

25.1%(2) $1.31(2)

EPS was also above the high end of guidance, with EPS growth exceeding revenue growth as our Ignite transformation helped drive productivity and efficiency.

+5.3% core(1)(2)

-1.6% FX, +2.3% M&A

flat y/y

+7% y/y

Capital

Allocation

$221M operating cash flow

$165M to purchase 1.3M shares

$114M invested in capex

$70M in dividends

(1) Core growth is reported growth adjusted for the effects of acquisitions and divestitures, and FX.

03 (2) Presented on a non-GAAP basis; reconciliations to closest GAAP equivalent provided on Agilent's Investor Relations website.

Q2 results by segment

$654M

Life Sciences and Diagnostics Markets Group (LDG)

Growth

+8% Reported

+3% Core (1)(2)

Operating Margin

19.7%(2)

+70 bps y/y

$713M

Agilent CrossLab Group

(ACG)

Growth

+7% Reported

+9% Core (1)(2)

Operating Margin

32.4%(2)

-10 bps y/y

$301M

Applied Markets Group (AMG)

Growth

-1% Reported

0% Core (1)(2)

Operating Margin

19.5%(2)

-150 bps y/y

Strong Cancer Dx, Small Molecule Pharma, and CDMO growth help to offset softness in academic research and US biopharma

Continued growth in lab activity drives excellent services and consumables growth

Instrument delivery delays otherwise offset growth led by Spectroscopy and GCMS performance

Core growth is reported growth adjusted for the effects of

acquisitions and divestitures, and FX.

Presented on a non-GAAP basis; reconciliations to closest GAAP equivalent provided on Agilent's Investor Relations website.

04

GEOGRAPHY PRODUCT TYPE SEGMENT

Q2 revenue mix Americas

Europe

26%(2)

REVENUE

6

(1)

33%(2)

REVENUE

(1)

GROWTH

REVENUE

Asia Pacific

2%

GROWTH

GROWTH

05

Core growth is reported growth adjusted for the effects of acquisitions and divestitures and FX; reconciliations to closest G AAP equivalent provided on Agilent's Investor Relations website.

% of Q2'25 Agilent revenue.

Disclaimer

Agilent Technologies Inc. published this content on May 28, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 28, 2025 at 20:57 UTC.